BCL-2 dependence is a favorable predictive marker of response to therapy for chronic lymphocytic leukemia.
Saved in:
| Title: | BCL-2 dependence is a favorable predictive marker of response to therapy for chronic lymphocytic leukemia. |
|---|---|
| Authors: | Chong SJF; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Ave, Boston, MA, 02215, USA.; Department of Physiology, NUS Centre for Cancer Research (N2CR), National University of Singapore (NUS), Singapore, Singapore.; Cancer Science Institute of Singapore, N2CR, NUS, Singapore, Singapore., Lu J; Medical Faculty Heidelberg, Heidelberg University, Heidelberg, Germany., Valentin R; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Ave, Boston, MA, 02215, USA.; Department of Hematology, Rigshospitalet, Copenhagen, Denmark., Lehmberg TZ; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Ave, Boston, MA, 02215, USA., Eu JQ; Cancer Science Institute of Singapore, N2CR, NUS, Singapore, Singapore., Wang J; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Ave, Boston, MA, 02215, USA., Zhu F; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Ave, Boston, MA, 02215, USA., Kong LR; Cancer Science Institute of Singapore, N2CR, NUS, Singapore, Singapore., Fernandes SM; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Ave, Boston, MA, 02215, USA., Zhang J; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Ave, Boston, MA, 02215, USA., Herbaux C; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Ave, Boston, MA, 02215, USA., Goh BC; Cancer Science Institute of Singapore, N2CR, NUS, Singapore, Singapore., Brown JR; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Ave, Boston, MA, 02215, USA., Niemann CU; Department of Hematology, Rigshospitalet, Copenhagen, Denmark., Huber W; European Molecular Biology Laboratory, Heidelberg, Germany., Zenz T; Department of Medical Oncology and Hematology, University of Zurich & University Hospital Zurich, Zurich, Switzerland., Davids MS; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Ave, Boston, MA, 02215, USA. matthew_davids@dfci.harvard.edu. |
| Source: | Molecular cancer [Mol Cancer] 2025 Mar 03; Vol. 24 (1), pp. 62. Date of Electronic Publication: 2025 Mar 03. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: BioMed Central Country of Publication: England NLM ID: 101147698 Publication Model: Electronic Cited Medium: Internet ISSN: 1476-4598 (Electronic) Linking ISSN: 14764598 NLM ISO Abbreviation: Mol Cancer Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1476-4598 |
|---|---|
| DOI: | 10.1186/s12943-025-02260-7 |
